Paracetamol Recall Notice: Addressing the Risk of Discolouration
Recall Details:
An recall has been issued after a number of patients reported discolouring tablets produced by Chelonia Healthcare Limited. This recall was issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) following complaints of discolouring tablets, which appeared to be discolored due to contamination. The recall is intended to prevent further harm to the patient by identifying batches of paracetamol tablets that contained potential.cb materials.
Recall Batch Information:
The recall is related to two batches: PC 2312010 and PC 2312011. Both batches were produced under the "Paracetamol 500mg Tablets" brand. The recall is expected to cover a total of 200 tablets (100 in each batch). The batches were distributed in October 2025. The recall has a significant expiry date of December 31, 2027.
Safety Concerns:
The recall was linked to contamination causing discoloration in the paracetamol tablets. The issue is described as a functional/ training-related contamination. The作用 of the medication is unaffected, but contamination lowers the risk of adverse reactions, including_tests or repair problems.
Negative News:
The recall has been issued as a precautionary measure to address the observed contamination. Any patient who has received discoloured tablets should contact their healthcare professional immediately and report the incident. A concise Yellow Card scheme (MHRASNC designate number SM-201RR0026) can be used to address the bad news.
Pressure on_trap to Continue:
The recall indicates that the production of paracetamol tablets is not entirely safe. It suggests that supply issues and potential risks exist, even though the risk of adverse reactions is known to be low.
Preventive Measures:
Chemists accompanying patients are being told to stop supplying recalled batches to患者. Patient safety is prioritized in this recall.
Conclusion on Paracetamol:
Paracetamol is widely available in the UK over-the-counter as one of the most commonly taken medications. Approximately 6,300 tonnes are sold annually, and it is available over-the-counter at pharmacies but may also be dispensed under prescription for those with long-term pain. The guidelines for use and handling of paracetamol remain in place.
Additional Notes:
The recall adds to ongoing safety concerns about the production of paracetamol and highlights the need for further investigation. This recall will help patients take advantage of the full benefit of paracetamol by ensuring they receive bottles that are unaffected by contamination.
